Terumo Corporation

Tokyo Stock Exchange 4543.T

Terumo Corporation Revenue for the year ending March 31, 2024: USD 6.09 B

Terumo Corporation Revenue is USD 6.09 B for the year ending March 31, 2024, a -1.34% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.
  • Terumo Corporation Revenue for the year ending March 31, 2023 was USD 6.17 B, a 6.86% change year over year.
  • Terumo Corporation Revenue for the year ending March 31, 2022 was USD 5.78 B, a 4.23% change year over year.
  • Terumo Corporation Revenue for the year ending March 31, 2021 was USD 5.54 B, a -5.22% change year over year.
  • Terumo Corporation Revenue for the year ending March 31, 2020 was USD 5.85 B, a 8.16% change year over year.
Key data
Date Revenue Gross Profit Operating Income EBIT
Market news
Loading...
Tokyo Stock Exchange: 4543.T

Terumo Corporation

CEO Mr. Hikaru Samejima
IPO Date Jan. 4, 2000
Location Japan
Headquarters 2-44-1, Hatagaya
Employees 30,207
Sector Health Care
Industries
Description

Terumo Corporation engages in the manufacture and sale of medical products and equipment worldwide. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents, intravascular ultrasound systems, imaging catheters, and others; coils, stents, and intrasaccular devices for treating cerebral aneurysm; embolization systems, aspiration catheters, and clot retrievers for treating ischemic stroke and others; oxygenators, cardio-pulmonary bypass systems, and others; and artificial vascular and stent grafts. The Medical Care Solutions Company segment provides syringes, infusion pumps, syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, pain management and nutritious food products, adhesion barriers, and others; blood glucose monitoring systems, disposable needles for pen-injector, insulin patch pumps, blood pressure monitors, digital thermometers, and others; and contract manufacturing of prefilled syringes, devices to pharmaceutical companies for use in drug kits, such as prefillable syringes, needles for pharmaceutical packaging business, and others. The Blood and Cell Technologies Company segment offers blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, cell expansion systems, and others. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was incorporated in 1921 and is headquartered in Tokyo, Japan.

Similar companies

7733.T

Olympus Corporation

USD 14.83

0.94%

1925.T

Daiwa House Industry Co., Ltd.

USD 29.64

1.11%

4568.T

Daiichi Sankyo Company, Limited

USD 26.30

0.47%

4503.T

Astellas Pharma Inc.

USD 9.60

0.25%

4519.T

Chugai Pharmaceutical Co., Ltd.

USD 43.03

0.75%

StockViz Staff

January 15, 2025

Any question? Send us an email